Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax-Reference-Cited by-同舟云学术

Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax

Published:2020-01-21 Issue:3 Volume:99 Page:501-511
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Wang Yu-Wen,Tsai Cheng-Hong,Lin Chien-Chin,Tien Feng-Ming,Chen Yu-Wen,Lin Hsing-Yu,Yao Ming,Lin Yun-Chu,Lin Chien-Ting,Cheng Chieh-Lung,Tang Jih-Luh,Chou Wen-Chien,Hou Hsin-An,Tien Hwei-Fang

Funder

Ministry of Science and Technology, Taiwan

Ministry of Health and Welfare

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-020-03911-z.pdf

Reference32 articles.

1. Dohner H, Weisdorf DJ, Bloomfield CD (2015) Acute Myeloid Leukemia. N Engl J Med 373(12):1136–1152. https://doi.org/10.1056/NEJMra1406184

2. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Lowenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447. https://doi.org/10.1182/blood-2016-08-733196

3. Shah A, Andersson TM, Rachet B, Bjorkholm M, Lambert PC (2013) Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study. Br J Haematol 162(4):509–516. https://doi.org/10.1111/bjh.12425

4. Thol F, Schlenk RF, Heuser M, Ganser A (2015) How I treat refractory and early relapsed acute myeloid leukemia. Blood 126(3):319–327. https://doi.org/10.1182/blood-2014-10-551911

5. Dombret H, Gardin C (2016) An update of current treatments for adult acute myeloid leukemia. Blood 127(1):53–61. https://doi.org/10.1182/blood-2015-08-604520

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations;Expert Review of Hematology;2024-09-13

2. Monocytic Differentiation in Acute Myeloid Leukemia Cells: Diagnostic Criteria, Biological Heterogeneity, Mitochondrial Metabolism, Resistance to and Induction by Targeted Therapies;International Journal of Molecular Sciences;2024-06-08

3. Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience;Frontiers in Oncology;2024-04-12

4. Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients;Journal of Clinical Medicine;2024-04-01

5. Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients;International Immunopharmacology;2024-01